Related Experiment Videos

Manidipine-delapril combination in the management of hypertension

Manuel Luque Otero1

  • 1Hypertension Unit, Hospital Clinico San Carlos, Complutense University, Madrid, Spain. mluqueo@telefonica.net

Vascular Health and Risk Management
|August 21, 2007
PubMed

Insights

Combining manidipine and delapril effectively lowers high blood pressure (BP). This fixed-dose combination offers greater antihypertensive effects and is well-tolerated, reducing side effects like ankle edema.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • High blood pressure (BP) is a leading global cardiovascular risk factor and cause of death.
  • Current guidelines recommend BP targets below 140/90 mmHg (130/80 mmHg for diabetics) to reduce cardiovascular risk.
  • Achieving BP targets often necessitates combination antihypertensive therapy.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of a fixed-dose combination of manidipine and delapril.
  • To compare the antihypertensive effect of the combination therapy versus monotherapy.

Main Methods:

  • The study assessed a new oral fixed combination of manidipine 10 mg/delapril 30 mg.
  • Efficacy was measured by the reduction in systolic and diastolic BP.
  • Tolerability and adverse effects were monitored.

Main Results:

  • The manidipine/delapril combination demonstrated a greater antihypertensive effect than either component alone.
  • In patients not responding to monotherapy, the combination achieved an average BP reduction of 16/10 mmHg.
  • The combination was well-tolerated, with adverse effects similar to monotherapy, but reduced ankle edema incidence.

Conclusions:

  • The fixed-dose combination of manidipine 10 mg/delapril 30 mg provides significant additive antihypertensive effects.
  • This combination therapy is well-tolerated and may reduce specific side effects like ankle edema.
  • It offers a valuable therapeutic option for achieving target blood pressure goals in hypertensive patients.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...